Then, three PANoptosis‐related signatures (APOD, GPC3, and SERPINE1) were identified to develop a RiskScore model, which demonstrated strong performance in evaluating the immunotherapy response and prognostic outcome of STAD patients. This evidence concerns the gene GPC3 and gastric adenocarcinoma.